Azitra vs Kiora Pharmaceuticals
AZTR and KPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AZTR and KPRX compare
Kiora Pharmaceuticals is the larger company, worth 1.5 times as much as Azitra ($5.4M against $3.7M).
Kiora Pharmaceuticals scores higher on the StockData Score (6 against 2 for Azitra), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AZTR | KPRX |
|---|---|---|
| Size and price | ||
| Market cap | $3.7M | $5.4M |
| Share price | $0.608 | $1.23 |
| Change, 1 year | 50.2% | −46.6% |
| Change, 5 years | – | −99.8% |
| Beta (5Y) | −2.26 | 0.80 |
| Employees | 13 | 3,500 |
| StockData Score | ||
| Total score | 2 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.8× | 0.4× (better) |
| FCF yield | −316% | −145% (better) |
| Profitability | ||
| Return on equity | −373% | −67.7% (better) |
| Return on invested capital | −1294% | −1063% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1220.4× | – |
| Current ratio | 3.11 | 7.91 (better) |
| Altman Z-score | −23.30 | −10.67 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −70.9% | – |
| Shareholder yield | −70.9% | 0.00% (better) |
| Ownership | ||
| Held by institutions | – | 25.0% |
| Held by insiders | 95.8% | 3.0% |
| Short interest, % of float | 121% | – |
Go deeper
- AZTR stock overview
- AZTR income statement
- AZTR valuation and score
- KPRX stock overview
- KPRX income statement
- KPRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.